Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

Launched by IMMUNOVANT SCIENCES GMBH · Aug 24, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called batoclimab for people with Thyroid Eye Disease, a condition that can cause eye bulging and discomfort. The trial has two parts: one part is observing participants who have completed earlier studies to see how long their symptoms remain improved after stopping treatment, while the other part involves giving batoclimab to participants to see how effective it is at reducing eye bulging.

To be eligible for this study, participants must have finished a previous study and should not need immediate surgery or other treatments for their eye condition during the trial. It’s important that those who join the treatment group have not stopped taking batoclimab permanently. Participants in the trial can expect regular check-ins to monitor their progress and learn more about how batoclimab works for their condition. This is a great opportunity for individuals looking for potential new treatments for their Thyroid Eye Disease.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• For all participants:
• • 1. Have completed the Week 24 visit of the feeder study.
• For participants assigned to the Open-label Treatment Cohort:
• • 1. Do not require immediate surgical intervention and is not planning corrective surgery/irradiation or medical therapy for TED during the course of the study.
• • 2. Did not permanently discontinue batoclimab
• • Additional inclusion criteria are defined in the protocol.
• Exclusion criteria:
• For all participants:
• • 1. In the Investigator's judgement, the benefits of entry in the study do not outweigh the risk.